- Home
- IMNN
IMNN
Imunon Inc.
as 05-15-2025 1:38pm EST
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | LAWRENCEVILLE |
| Market Cap: | 12.1M | IPO Year: | 1985 |
| Target Price: | $15.50 | AVG Volume (30 days): | 209.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.64 - $3.65 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Imunon Inc. News
IMNN Breaking Stock News: Dive into IMNN Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 hours ago
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19
Zacks Small Cap Research
a day ago
IMNN: First Site Activated for Phase 3 OVATION 3 Trial…
GuruFocus.com
2 days ago
Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Thomson Reuters StreetEvents
2 days ago
Q1 2025 Imunon Inc Earnings Call
GlobeNewswire
3 days ago
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
7 days ago
IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
GlobeNewswire
9 days ago
IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology
GlobeNewswire
10 days ago
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025
Compare IMNN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNN Imunon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.